Ocugen Inc. to present pre-clinical data for OCU410 at 2nd Annual Dry AMD Therapeutic Development Conference - Seite 2
About Dry AMD
Dry AMD is the most prevalent, chronic form of age-related macular degeneration, accounting for about 90 percent of all cases. Dry AMD is a progressive disease, taking several years to go through
three stages: early (no symptoms), intermediate (mild blurriness in central vision or difficulty seeing in low light) and late (distorted vision, a blurry area near the center of one’s vision).
According to the National Eye Institute, there are no treatments available for late dry AMD.
About Ocugen
Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19.
Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug — “one to many,” and our novel biologic product candidate aims to offer better
therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. We are co-developing Bharat Biotech’s COVAXIN vaccine
candidate for COVID-19 in the U.S. and Canadian markets. For more information, please visit www.ocugen.com.
Lesen Sie auch
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. Such forward-looking
statements within this press release include, without limitation, qualitative assessments of available data, potential benefits of our product candidates, if approved, expectations for clinical
trials, and anticipated timing of clinical trial readouts and regulatory submissions, including with respect to our OCU410 product candidate. We may, in some cases, use terms such as “predicts,”
“believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of
future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to
differ materially from our current expectations, such as the uncertainties inherent in research and development, including our ability to meet anticipated clinical endpoints, commencement and/or
completion dates for clinical trials or regulatory submission dates, including the risk that such dates are not met due to impacts from the ongoing COVID-19 pandemic, and risks associated with
preliminary and interim data, including the possibility of unfavorable new clinical trial data or unfavorable results from further analyses of existing clinical trial data, as well as market and
other conditions. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (the “SEC”), including the risk factors
described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of
the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information,
future events or otherwise, after the date of this press release.